Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential brentuximab vedotin followed by ABVD in untreated classical Hodgkin lymphoma
2012-002012-46Phase 2Active
- Sponsor
- AOU Policlinico di Modena
- Start
- Jun 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by AOU Policlinico di Modena. Started Jun 2012; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2012-002012-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002012-46.